TICKERNERD
Menu
IMMXIMMXHealthcare · Biotechnology

IMMX Stock Forecast: Immix Biopharma, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$9.29
−2.11% on the day

The 7 Wall Street analysts covering Immix Biopharma, Inc. hold a median 12-month price target of $25 — +163.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 33 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$799.2M
Ticker Nerd rank
33 / 100
Median analyst target
$25
Analysts covering
7
Revenue$0.0
Operating income−$12.5M
Net income−$11.6M
Free cash flow−$11.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.2%
1M
−29.9%
YTD
+77.6%
1Y
+265.7%
From 52W high
−35.8%
From 52W low
+274.6%
$2
$14
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IMMX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Immix Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
33 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
84
Value
63
Quality
63
Size
48
Volatility
36
Revisions
35
Issuance
28
Growth
27
Accruals
21

Momentum (84): The shares have been drifting up relative to others.

Accruals (21): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IMMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IMMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$5$10$15$20$25$30$35Jan 26Apr 26Jul 26Oct 26IMMXHigh $30Median $25Low $17

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says7 analysts
7 Buy0 Hold0 Sell
Low $17Median $25High $30

The green dot is the last close — the median target sits +163.7% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
29 Sept 2026NeedhamMaintainsBuy—
29 Sept 2026NeedhamMaintainsBuy$21 → $30
15 Sept 2026MizuhoMaintainsOutperform—
15 Sept 2026MizuhoMaintainsOutperform$15 → $26
11 Aug 2026Morgan StanleyMaintainsOverweight$20 → $19
11 Aug 2026Morgan StanleyMaintainsOverweight—
10 Aug 2026HC Wainwright & Co.MaintainsBuy—
10 Aug 2026HC Wainwright & Co.MaintainsBuy$20 → $25
22 July 2026NeedhamInitiatesBuy—
22 July 2026NeedhamInitiatesBuy$21
18 June 2026B of A SecuritiesInitiatesBuy—
18 June 2026B of A SecuritiesInitiatesBuy$27
17 June 2026LifeSci CapitalInitiatesOutperform—
22 May 2026HC Wainwright & Co.MaintainsBuy—
30 Mar 2026HC Wainwright & Co.ReiteratesBuy—
30 Mar 2026MizuhoMaintainsOutperform—
27 Mar 2026CitizensReiteratesMarket Outperform—
27 Mar 2026HC Wainwright & Co.MaintainsBuy—
25 Mar 2026Morgan StanleyInitiatesOverweight—
9 Mar 2026CitizensInitiatesMarket Outperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IMMX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IMMX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Immix Biopharma, Inc. returned +265.7% against +16.2% for the S&P 500, dividends included.

IMMX vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500600Jan 26Apr 26Jul 26Oct 26IMMXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IMMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
1
Fundamentals

Immix Biopharma, Inc. (IMMX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−10.8×

Cheaper than 94% of US stocks

Price / sales
—
Price / book
3.0×

Cheaper than 32% of US stocks

EV / EBITDA
−11.1×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−34.2%

Higher than 26% of US stocks

Return on assets
−20.5%

Higher than 19% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Immix Biopharma, Inc. (IMMX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Immix Biopharma, Inc. has a market value of $799.2M and an enterprise value of $458.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$39.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$39.1M.

  • Shares outstanding: 71.2M.

  • Trailing P/E: −10.8×; forward P/E: −11.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Immix Biopharma, Inc. employs 21 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

IMMX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IMMXImmix Biopharma, Inc.$799.2M
33
GERNGeron Corp.$781.5M
53
APMDApnimed, Inc.$758.4M
1
ANNXAnnexon, Inc.$758.3M
38
LXRXLexicon Pharmaceuticals, Inc.$783.1M
71
OBXObsidian Therapeutics, Inc.$755.5M
59
GYREGyre Therapeutics, Inc.$753.7M
45

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Immix Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IMMX news & analysis

Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference

GlobeNewsWire · 5 Oct 2026neutral

Immix Biopharma, Inc. announced it will present at the 45th Annual J.P. Morgan Healthcare Conference, scheduled for January 11-14, 2027, in San Francisco, CA. The company made the announcement on October 5, 2026.

Why it matters — Participation in a major industry conference gives Immix Biopharma a platform to present to healthcare investors and industry peers, which may increase visibility for the company.

Immix Biopharma Reports 89% Complete Response in NXC-201 AL Amyloidosis Study

MarketBeat · 5 Oct 2026positive

Immix Biopharma reported updated clinical data for NXC-201, its investigational CAR T-cell therapy for relapsed or refractory light-chain (AL) amyloidosis. The company also outlined plans for a biologics license application, a frontline study, and a targeted commercial launch strategy.

Why it matters — This update signals clinical progress for NXC-201 and lays out the company's regulatory and commercialization roadmap, which is significant for IMMX watchers tracking the therapy's advancement.

Immix Biopharma Announces Closing of $125 Million Underwritten Offering of Common Stock

GlobeNewsWire · 30 Sept 2026neutral

Immix Biopharma announced the closing of its previously announced underwritten registered offering of 11,363,637 shares of common stock at a public offering price of $11.00 per share, raising $125 million. The offering was announced in Los Angeles on September 30, 2026.

Why it matters — This capital raise provides funding for the company, though it also results in dilution of existing shareholders.

Immix Biopharma, Inc. (IMMX) Shareholder/Analyst Call Transcript

Seeking Alpha · 29 Sept 2026neutral

Immix Biopharma, Inc. held a shareholder/analyst call, and a transcript of the call was published by Seeking Alpha. The transcript provides a record of the company's discussion with shareholders and analysts.

Why it matters — A watcher of IMMX would care because the call transcript offers direct insight into management's commentary and topics addressed with analysts and shareholders.

Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

GlobeNewsWire · 29 Sept 2026neutral

Immix Biopharma announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share, with expected gross proceeds of $125 million before underwriting discounts, commissions, and offering expenses. The offering is expected to close on or about September 30, 2026, subject to customary closing conditions.

Why it matters — This capital raise provides Immix Biopharma with approximately $125 million in gross proceeds, which is significant for a company positioned in the relapsed/refractory AL Amyloidosis space.

FAQ

Frequently asked questions about IMMX stock

What is the IMMX stock price forecast for 2026-2027?

The 7 Wall Street analysts covering Immix Biopharma, Inc. have a median 12-month price target of $25, with estimates ranging from $17 to $30. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IMMX stock a buy right now?

Of the 7 analysts covering Immix Biopharma, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Immix Biopharma, Inc. 33 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IMMX?

As at 8 Oct 2026, Immix Biopharma, Inc. ranks 33 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (84 of 100).

Will IMMX stock go up?

No one can know that. What the data says: the median 12-month target from 7 analysts implies +163.7% from the last close, and Ticker Nerd's factor model ranks Immix Biopharma, Inc. 33 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IMMX stock forecast for 2030?

No analyst covering Immix Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IMMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $30 over the next 12 months.

How has IMMX stock performed over the past year?

Immix Biopharma, Inc. returned +265.7% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Immix Biopharma, Inc. do?

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers.

What is the latest news on IMMX?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Immix Biopharma to Participate in the 45th Annual J.P. Morgan Healthcare Conference". Immix Biopharma, Inc. announced it will present at the 45th Annual J.P. Morgan Healthcare Conference, scheduled for January 11-14, 2027, in San Francisco, CA. The company made the announcement on October 5, 2026.

Company

About Immix Biopharma, Inc.

Immix Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cell therapies and tissue-specific therapeutics for serious diseases, with an emphasis on AL amyloidosis, immune-mediated conditions, and select cancers. Immix Biopharma’s current pipeline is led by NXC-201, a BCMA-targeted CAR-T cell therapy being evaluated for AL amyloidosis and related plasma-cell disorders, and IMX-110, a tissue-specific therapeutic studied in solid tumors. The company also works on immune-dysregulated and inflammatory diseases through its proprietary therapeutic platforms. Immix Biopharma operates in the biotechnology sector, where its role is centered on advancing investigational treatments designed to address high-unmet-need conditions through cell therapy and precision drug delivery approaches. Founded in 2012 and headquartered in Los Angeles, California, Immix Biopharma is positioned as a development-stage company focused on translating specialized oncology and immunology research into clinical programs.

CEO Dr. Ilya Rachman M.B.A., M.D., Ph.D. · 21 employees · United States · https://www.immixbio.com